Extracellular vesicles versus synthetic nanoparticles for drug delivery
- 7 January 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Materials
- Vol. 6 (2), 103-106
- https://doi.org/10.1038/s41578-020-00277-6
Abstract
Cell-released biological nanoparticles, that is, extracellular vesicles (EVs), are emerging drug carriers with high complexity. EV-based drug delivery exploits intrinsic mechanisms for molecular transport in the body. Integrating EV biology and manufacturing with clinical insights from synthetic nanoparticles is likely to substantially advance the field of drug delivery.Keywords
This publication has 11 references indexed in Scilit:
- Extracellular vesicles as drug delivery systems: Why and how?Advanced Drug Delivery Reviews, 2020
- Spatial and temporal tracking of cardiac exosomes in mouse using a nano-luciferase-CD63 fusion proteinCommunications Biology, 2020
- Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backboneNature Biomedical Engineering, 2020
- Reproducibility of GMP-compliant production of therapeutic stressed peripheral blood mononuclear cell-derived secretomes, a novel class of biological medicinal productsStem Cell Research & Therapy, 2020
- Defining mesenchymal stromal cell (MSC)‐derived small extracellular vesicles for therapeutic applicationsJournal of Extracellular Vesicles, 2019
- Clinical cancer nanomedicineNano Today, 2019
- Extracellular vesicle-based drug delivery systems for cancer treatmentTheranostics, 2019
- What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2018
- Shedding light on the cell biology of extracellular vesiclesNature Reviews Molecular Cell Biology, 2018
- Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical UseInternational Journal of Molecular Sciences, 2017